Aprea expands IP portfolio to 28 issued, 30 pending patents for oncology programs

Aprea Therapeutics, Inc.

Total portfolio now 28 issued and 30 pending patents across WEE1 and ATR inhibitor programs.
WEE1 program: 2 pending US apps, 1 provisional, 2 granted non-US patents (Australia, Korea), 12 pending non-US; expiry 2047.
ATR program: 4 granted US patents, 22 granted non-US, 13 pending non-US; granted expire 2035-2037, pending could extend to 2045.
Lead WEE1 inhibitor APR-1051 in ACESOT-1051 Phase 1 trial for advanced solid tumors with gene alterations.
ATRN-119 RP2D set at 1,100 mg once daily in 2025; study closed to focus on APR-1051, combo approaches considered.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.